mephenytoin has been researched along with Liver Diseases in 3 studies
Mephenytoin: An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias.
mephenytoin : An imidazolidine-2,4-dione (hydantoin) in which the imidazolidine nucleus carries a methyl group at N-3 and has ethyl and phenyl substituents at C-5. An anticonvulsant, it is no longer available in the USA or the UK but is still studied largely because of its interesting hydroxylation polymorphism.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mephenytoin metabolism was significantly decreased in both patients with mild liver disease (Child-Pugh score of 5/6) (-63% [95% confidence interval (CI), -86% to -40%]; P = ." | 2.72 | Liver disease selectively modulates cytochrome P450--mediated metabolism. ( Branch, RA; Chaves-Gnecco, D; Frye, RF; Matzke, GR; Rabinovitz, M; Shaikh, OS; Zgheib, NK, 2006) |
| " As a consequence, alteration in metabolism of specific drugs cannot be easily predicted or appropriate dosage adjustment recommendations made." | 2.69 | Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6. ( Adedoyin, A; Arns, PA; Branch, RA; Richards, WO; Wilkinson, GR, 1998) |
| " The omeprazole metabolic ratio may serve the double purpose of phenotyping for CYP2C19 and to individualize dosing in omeprazole-treated patients." | 1.29 | Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. ( Brockmöller, J; Esdorn, F; Roots, I; Rost, KL, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Frye, RF | 1 |
| Zgheib, NK | 1 |
| Matzke, GR | 1 |
| Chaves-Gnecco, D | 1 |
| Rabinovitz, M | 1 |
| Shaikh, OS | 1 |
| Branch, RA | 2 |
| Rost, KL | 1 |
| Brockmöller, J | 1 |
| Esdorn, F | 1 |
| Roots, I | 1 |
| Adedoyin, A | 1 |
| Arns, PA | 1 |
| Richards, WO | 1 |
| Wilkinson, GR | 1 |
2 trials available for mephenytoin and Liver Diseases
| Article | Year |
|---|---|
Liver disease selectively modulates cytochrome P450--mediated metabolism.
Topics: Administration, Oral; Adult; Anticonvulsants; Antihypertensive Agents; Caffeine; Case-Control Studie | 2006 |
Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6.
Topics: Adult; Aged; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P- | 1998 |
1 other study available for mephenytoin and Liver Diseases
| Article | Year |
|---|---|
Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Ulcer A | 1995 |